<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1  Adjuvant Treatment in Early Breast Cancer<BR>                     <BR>                        The Intergroup Exemestane Study 031 (IES) was a randomized, double-blind, multicenter, multinational study comparing exemestane (25 mg/day) vs. tamoxifen (20 or 30 mg/day) in postmenopausal women with early breast cancer. Patients who remained disease-free after receiving adjuvant tamoxifen therapy for 2 to 3 years were randomized to receive an additional 3 or 2 years of AROMASIN or tamoxifen to complete a total of 5 years of hormonal therapy.<BR>                        The primary objective of the study was to determine whether, in terms of disease-free survival, it was more effective to switch to AROMASIN rather than continuing tamoxifen therapy for the remainder of five years. Disease-free survival was defined as the time from randomization to time of local or distant recurrence of breast cancer, contralateral invasive breast cancer, or death from any cause.<BR>                        The secondary objectives were to compare the two regimens in terms of overall survival and long-term tolerability. Time to contralateral invasive breast cancer and distant recurrence-free survival were also evaluated.<BR>                        A total of 4724 patients in the intent-to-treat (ITT) analysis were randomized to AROMASIN (exemestane tablets) 25 mg once daily (N = 2352) or to continue to receive tamoxifen once daily at the same dose received before randomization (N = 2372). Demographics and baseline tumor characteristics are presented in Table 5. Prior breast cancer therapy is summarized in Table 6.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="90%"><BR>                           <caption>Table 5. Demographic and  Baseline Tumor Characteristics from  the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)</caption><BR>                           <col width="60%" align="left" valign="top"/><BR>                           <col width="20%" align="center" valign="top"/><BR>                           <col width="20%" align="center" valign="top"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule">Parameter</th><BR>                                 <th styleCode="Rrule">Exemestane<br/> (N = 2352)</th><BR>                                 <th styleCode="Rrule">Tamoxifen<br/>(N = 2372)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Age (years):</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Median age (range)</td><BR>                                 <td styleCode="Rrule">63.0  (38.0 &#8211; 96.0)</td><BR>                                 <td styleCode="Rrule">63.0  (31.0 &#8211; 90.0)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Race, n (%):</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Caucasian</td><BR>                                 <td styleCode="Rrule">2315  (98.4)</td><BR>                                 <td styleCode="Rrule">2333    (98.4)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Hispanic</td><BR>                                 <td styleCode="Rrule">13    (0.6)</td><BR>                                 <td styleCode="Rrule">13      (0.5)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Asian</td><BR>                                 <td styleCode="Rrule">10    (0.4)</td><BR>                                 <td styleCode="Rrule">9      (0.4)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Black</td><BR>                                 <td styleCode="Rrule"> 7    (0.3)</td><BR>                                 <td styleCode="Rrule">10      (0.4)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Other/not reported</td><BR>                                 <td styleCode="Rrule"> 7    (0.3)</td><BR>                                 <td styleCode="Rrule">7      (0.3)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Nodal status, n (%):</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Negative</td><BR>                                 <td styleCode="Rrule">1217      (51.7)</td><BR>                                 <td styleCode="Rrule">1228(51.8)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Positive</td><BR>                                 <td styleCode="Rrule">1051      (44.7)</td><BR>                                 <td styleCode="Rrule">1044(44.0)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;1&#8211;3 Positive nodes</td><BR>                                 <td styleCode="Rrule">721      (30.7)</td><BR>                                 <td styleCode="Rrule">708            (29.8)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;4&#8211;9 Positive nodes</td><BR>                                 <td styleCode="Rrule">239      (10.2)</td><BR>                                 <td styleCode="Rrule">244       (10.3)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;&gt;9 Positive nodes</td><BR>                                 <td styleCode="Rrule">88      (3.7)</td><BR>                                 <td styleCode="Rrule">86           (3.6)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Not reported</td><BR>                                 <td styleCode="Rrule">3          (0.1)</td><BR>                                 <td styleCode="Rrule">6      (0.3)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Unknown or missing</td><BR>                                 <td styleCode="Rrule">84      (3.6)</td><BR>                                 <td styleCode="Rrule">100              (4.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Histologic type, n (%):</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Infiltrating ductal</td><BR>                                 <td styleCode="Rrule">1777      (75.6)</td><BR>                                 <td styleCode="Rrule">1830       (77.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Infiltrating lobular</td><BR>                                 <td styleCode="Rrule">341      (14.5)</td><BR>                                 <td styleCode="Rrule">321       (13.5)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Other</td><BR>                                 <td styleCode="Rrule">231        (9.8)</td><BR>                                 <td styleCode="Rrule">213         (9.0)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Unknown or missing</td><BR>                                 <td styleCode="Rrule">3        (0.1)</td><BR>                                 <td styleCode="Rrule">8         (0.3)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Receptor status<footnote ID="t5fn1"><BR>                                          <content styleCode="italics">Results for receptor status include the results of the post-randomization testing of specimens from subjects for whom receptor status was unknown at randomization.</content><BR>                                       </footnote>, n (%):</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">ER and PgR Positive</td><BR>                                 <td styleCode="Rrule">1331    (56.6)</td><BR>                                 <td styleCode="Rrule">1319        (55.6)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">ER Positive and PgR Negative/Unknown</td><BR>                                 <td styleCode="Rrule">677    (28.8)</td><BR>                                 <td styleCode="Rrule">692        (29.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">ER Unknown and PgR Positive<footnote ID="t5fn2"><BR>                                       <content styleCode="italics">Only one subject in the exemestane group had unknown ER status and positive PgR status.</content><BR>                                    </footnote>/Unknown</td><BR>                                 <td styleCode="Rrule">288    (12.2)</td><BR>                                 <td styleCode="Rrule">291        (12.3)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">ER Negative and PgR Positive</td><BR>                                 <td styleCode="Rrule">6      (0.3)</td><BR>                                 <td styleCode="Rrule">7          (0.3)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">ER Negative and PgR Negative/Unknown (none  positive)</td><BR>                                 <td styleCode="Rrule">48     (2.0)</td><BR>                                 <td styleCode="Rrule">58          (2.4)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Missing</td><BR>                                 <td styleCode="Rrule">2     (0.1)</td><BR>                                 <td styleCode="Rrule">5           (0.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Tumor Size, n (%):</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#8804; 0.5 cm</td><BR>                                 <td styleCode="Rrule">58     (2.5)</td><BR>                                 <td styleCode="Rrule"> 46       (1.9)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&gt; 0.5 &#8211; 1.0 cm</td><BR>                                 <td styleCode="Rrule">315   (13.4)</td><BR>                                 <td styleCode="Rrule">302     (12.7)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&gt; 1.0 &#8211; 2 cm</td><BR>                                 <td styleCode="Rrule">1031   (43.8)</td><BR>                                 <td styleCode="Rrule">1033    (43.5)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&gt; 2.0 &#8211; 5.0 cm</td><BR>                                 <td styleCode="Rrule">833   (35.4)</td><BR>                                 <td styleCode="Rrule">883    (37.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&gt; 5.0 cm</td><BR>                                 <td styleCode="Rrule">62     (2.6)</td><BR>                                 <td styleCode="Rrule">59       (2.5)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Not reported</td><BR>                                 <td styleCode="Rrule">53     (2.3)</td><BR>                                 <td styleCode="Rrule">49       (2.1)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Tumor Grade, n (%):</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">G1</td><BR>                                 <td styleCode="Rrule">397   (16.9)</td><BR>                                 <td styleCode="Rrule">393  (16.6)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">G2</td><BR>                                 <td styleCode="Rrule">977   (41.5)</td><BR>                                 <td styleCode="Rrule">1007  (42.5)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">G3</td><BR>                                 <td styleCode="Rrule">454   (19.3)</td><BR>                                 <td styleCode="Rrule">428  (18.0)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">G4</td><BR>                                 <td styleCode="Rrule">23     (1.0)</td><BR>                                 <td styleCode="Rrule">19    (0.8)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Unknown/Not Assessed/Not  reported</td><BR>                                 <td styleCode="Rrule"> 501   (21.3)</td><BR>                                 <td styleCode="Rrule">525  (22.1)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="90%"><BR>                           <caption>Table 6. Prior Breast Cancer Therapy of Patients in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)</caption><BR>                           <col width="60%" align="left" valign="top"/><BR>                           <col width="20%" align="center" valign="top"/><BR>                           <col width="20%" align="center" valign="top"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule">Parameter</th><BR>                                 <th styleCode="Rrule">Exemestane<br/> (N = 2352)</th><BR>                                 <th styleCode="Rrule">Tamoxifen<br/>(N = 2372)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Type of surgery, n (%):</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Mastectomy</td><BR>                                 <td styleCode="Rrule">1232   (52.4)</td><BR>                                 <td styleCode="Rrule">1242      (52.4)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Breast-conserving</td><BR>                                 <td styleCode="Rrule">1116   (47.4)</td><BR>                                 <td styleCode="Rrule">1123      (47.3)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Unknown or missing</td><BR>                                 <td styleCode="Rrule">4     (0.2)</td><BR>                                 <td styleCode="Rrule">7          (0.3)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Radiotherapy to the breast, n (%):</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Yes</td><BR>                                 <td styleCode="Rrule">1524   (64.8)</td><BR>                                 <td styleCode="Rrule">1523      (64.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">No</td><BR>                                 <td styleCode="Rrule">824   (35.5)</td><BR>                                 <td styleCode="Rrule">843      (35.5)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Not reported</td><BR>                                 <td styleCode="Rrule">4     (0.2)</td><BR>                                 <td styleCode="Rrule">6          (0.3)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Prior therapy, n (%):</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Chemotherapy</td><BR>                                 <td styleCode="Rrule">774    (32.9)</td><BR>                                 <td styleCode="Rrule">769      (32.4)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Hormone replacement therapy</td><BR>                                 <td styleCode="Rrule">567   (24.1)</td><BR>                                 <td styleCode="Rrule">561      (23.7)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Bisphosphonates</td><BR>                                 <td styleCode="Rrule">43     (1.8)</td><BR>                                 <td styleCode="Rrule">34      (1.4)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Duration of tamoxifen therapy at randomization (months):</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Median (range)</td><BR>                                 <td styleCode="Rrule">28.5  (15.8 &#8211; 52.2)</td><BR>                                 <td styleCode="Rrule">28.4  (15.6 &#8211; 63.0)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Tamoxifen dose, n (%):</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">20 mg</td><BR>                                 <td styleCode="Rrule">2270      (96.5)</td><BR>                                 <td styleCode="Rrule">2287      (96.4)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">30 mg<footnote ID="t6fn1"><BR>                                       <content styleCode="italics">The 30 mg dose was used only in Denmark, where this dose was the standard of care.</content><BR>                                    </footnote><BR>                                 </td><BR>                                 <td styleCode="Rrule">78     (3.3)</td><BR>                                 <td styleCode="Rrule">75        (3.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Not reported</td><BR>                                 <td styleCode="Rrule">4      (0.2)</td><BR>                                 <td styleCode="Rrule">10       (0.4)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>After a median duration of therapy of 27 months and with a median follow-up of 34.5 months, 520 events were reported, 213 in the AROMASIN group and 307 in the tamoxifen group (Table 7).<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="90%"><BR>                           <caption>Table 7. Primary Endpoint Events (ITT Population)</caption><BR>                           <col width="34%" align="left" valign="top"/><BR>                           <col width="33%" align="center" valign="top"/><BR>                           <col width="33%" align="center" valign="top"/><BR>                           <thead><BR>                              <tr styleCode="Botrule"><BR>                                 <th styleCode="Lrule Rrule" valign="bottom">Event</th><BR>                                 <th styleCode="Rrule" colspan="2">First Events<br/> N (%)</th><BR>                              </tr><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule"/><BR>                                 <th styleCode="Rrule">Exemestane<br/>(N = 2352)</th><BR>                                 <th styleCode="Rrule">Tamoxifen<br/>(N = 2372)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Loco-regional recurrence</td><BR>                                 <td styleCode="Rrule">34      (1.45)</td><BR>                                 <td styleCode="Rrule">45      (1.90)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Distant recurrence</td><BR>                                 <td styleCode="Rrule">126      (5.36)</td><BR>                                 <td styleCode="Rrule">183      (7.72)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Second primary &#8211; contralateral breast cancer</td><BR>                                 <td styleCode="Rrule">7      (0.30)</td><BR>                                 <td styleCode="Rrule">25      (1.05)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Death &#8211; breast cancer</td><BR>                                 <td styleCode="Rrule">1      (0.04)</td><BR>                                 <td styleCode="Rrule">6      (0.25)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Death &#8211; other reason</td><BR>                                 <td styleCode="Rrule">41      (1.74)</td><BR>                                 <td styleCode="Rrule">43   (1.81)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Death &#8211; missing/unknown</td><BR>                                 <td styleCode="Rrule">3      (0.13)</td><BR>                                 <td styleCode="Rrule">5   (0.21)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Ipsilateral breast cancer</td><BR>                                 <td styleCode="Rrule">1      (0.04)</td><BR>                                 <td styleCode="Rrule">0</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Total  number of events</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"><BR>                                    <content styleCode="bold">213      (9.06)</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"><BR>                                    <content styleCode="bold">307       (12.94)</content><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Disease-free survival in the intent-to-treat population was statistically significantly improved [Hazard Ratio (HR) = 0.69, 95% CI: 0.58, 0.82, P = 0.00003, Table 8, Figure 1] in the AROMASIN arm compared to the tamoxifen arm. In the hormone receptor-positive subpopulation representing about 85% of the trial patients, disease-free survival was also statistically significantly improved (HR = 0.65, 95% CI: 0.53, 0.79, P = 0.00001) in the AROMASIN arm compared to the tamoxifen arm. Consistent results were observed in the subgroups of patients with node negative or positive disease, and patients who had or had not received prior chemotherapy. Overall survival was not significantly different in the two groups, with 116 deaths occurring in the AROMASIN group and 137 in the tamoxifen group.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="90%"><BR>                           <caption>Table 8. Efficacy Results from the IES Study in Postmenopausal Women with Early Breast Cancer</caption><BR>                           <col width="34%" align="left" valign="top"/><BR>                           <col width="33%" align="left" valign="top"/><BR>                           <col width="33%" align="left" valign="top"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule" valign="bottom">ITT Population</th><BR>                                 <th styleCode="Rrule">Hazard Ratio<br/>(95% CI)</th><BR>                                 <th styleCode="Rrule">p-value<br/>(log-rank test)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Disease-free survival</td><BR>                                 <td styleCode="Rrule">0.69 (0.58&#8211;0.82)</td><BR>                                 <td styleCode="Rrule">0.00003</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Time to contralateral breast cancer</td><BR>                                 <td styleCode="Rrule">0.32 (0.15&#8211;0.72)</td><BR>                                 <td styleCode="Rrule">0.00340</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Distant recurrence-free survival</td><BR>                                 <td styleCode="Rrule">0.74 (0.62&#8211;0.90)</td><BR>                                 <td styleCode="Rrule">0.00207</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Overall survival</td><BR>                                 <td styleCode="Rrule">0.86 (0.67&#8211;1.10)</td><BR>                                 <td styleCode="Rrule">0.22962</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">ER and/or PgR positive</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Disease-free survival</td><BR>                                 <td styleCode="Rrule">0.65 (0.53&#8211;0.79)</td><BR>                                 <td styleCode="Rrule">0.00001</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Time to contralateral breast cancer</td><BR>                                 <td styleCode="Rrule">0.22 (0.08&#8211;0.57)</td><BR>                                 <td styleCode="Rrule">0.00069</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Distant recurrence-free survival</td><BR>                                 <td styleCode="Rrule">0.73 (0.59&#8211;0.90)</td><BR>                                 <td styleCode="Rrule">0.00367</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Overall survival</td><BR>                                 <td styleCode="Rrule">0.88 (0.67&#8211;1.17)</td><BR>                                 <td styleCode="Rrule">0.37460</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" styleCode="Noautorules"><BR>                           <col width="100%" align="center" valign="top"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">Figure 1. Disease-Free Survival in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <renderMultiMedia referencedObject="MM2"/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                     <BR>                        <BR>                           Figure 1<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.2  Treatment of Advanced Breast Cancer<BR>                     <BR>                        Exemestane 25 mg administered once daily was evaluated in a randomized double-blind, multicenter, multinational comparative study and in two multicenter single-arm studies of postmenopausal women with advanced breast cancer who had disease progression after treatment with tamoxifen for metastatic disease or as adjuvant therapy. Some patients also have received prior cytotoxic therapy, either as adjuvant treatment or for metastatic disease.<BR>                        The primary purpose of the three studies was evaluation of objective response rate (complete response [CR] and partial response [PR]). Time to tumor progression and overall survival were also assessed in the comparative trial. Response rates were assessed based on World Health Organization (WHO) criteria, and in the comparative study, were submitted to an external review committee that was blinded to patient treatment. In the comparative study, 769 patients were randomized to receive AROMASIN (exemestane tablets) 25 mg once daily (N = 366) or megestrol acetate 40 mg four times daily (N = 403). Demographics and baseline characteristics are presented in Table 9.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="90%"><BR>                           <caption>Table 9. Demographics and Baseline Characteristics from the Comparative Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Tamoxifen Therapy</caption><BR>                           <col width="50%" align="left" valign="top"/><BR>                           <col width="25%" align="left" valign="top"/><BR>                           <col width="25%" align="left" valign="top"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule">Parameter</th><BR>                                 <th styleCode="Rrule">AROMASIN<br/>(N = 366)</th><BR>                                 <th styleCode="Rrule">Megestrol Acetate<br/>(N = 403)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" valign="bottom">Median Age (range)</td><BR>                                 <td styleCode="Rrule" valign="bottom">65 (35&#8211;89)</td><BR>                                 <td styleCode="Rrule" valign="bottom">65 (30&#8211;91)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">ECOG Performance Status</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;0</td><BR>                                 <td styleCode="Rrule">167 (46%)</td><BR>                                 <td styleCode="Rrule">187 (46%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;1</td><BR>                                 <td styleCode="Rrule">162 (44%)</td><BR>                                 <td styleCode="Rrule">172 (43%)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;2</td><BR>                                 <td styleCode="Rrule">34 (9%)</td><BR>                                 <td styleCode="Rrule">42 (10%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Receptor Status</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;ER and/or PgR +</td><BR>                                 <td styleCode="Rrule">246 (67%)</td><BR>                                 <td styleCode="Rrule">274 (68%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;ER and PgR unknown</td><BR>                                 <td styleCode="Rrule">116 (32%)</td><BR>                                 <td styleCode="Rrule">128 (32%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;Responders to prior tamoxifen</td><BR>                                 <td styleCode="Rrule">68 (19%)</td><BR>                                 <td styleCode="Rrule">85 (21%)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;NE for response to prior tamoxifen</td><BR>                                 <td styleCode="Rrule">46 (13%)</td><BR>                                 <td styleCode="Rrule">41 (10%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Site of Metastasis</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Visceral &#177; other sites</td><BR>                                 <td styleCode="Rrule">207 (57%)</td><BR>                                 <td styleCode="Rrule">239 (59%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Bone only</td><BR>                                 <td styleCode="Rrule">61 (17%)</td><BR>                                 <td styleCode="Rrule">73 (18%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Soft tissue only</td><BR>                                 <td styleCode="Rrule">54 (15%)</td><BR>                                 <td styleCode="Rrule">51 (13%)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Bone &amp; soft tissue</td><BR>                                 <td styleCode="Rrule">43 (12%)</td><BR>                                 <td styleCode="Rrule">38 (9%)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Measurable Disease</td><BR>                                 <td styleCode="Rrule">287 (78%)</td><BR>                                 <td styleCode="Rrule">314 (78%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Prior Tamoxifen Therapy</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Adjuvant or Neoadjuvant</td><BR>                                 <td styleCode="Rrule">145 (40%)</td><BR>                                 <td styleCode="Rrule">152 (38%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Advanced Disease, Outcome</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;CR, PR, or SD &#8805; 6 months</td><BR>                                 <td styleCode="Rrule">179 (49%)</td><BR>                                 <td styleCode="Rrule">210 (52%)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;SD &lt; 6 months, PD or NE</td><BR>                                 <td styleCode="Rrule">42 (12%)</td><BR>                                 <td styleCode="Rrule">41 (10%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Prior Chemotherapy</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;For advanced disease &#177; adjuvant</td><BR>                                 <td styleCode="Rrule">58 (16%)</td><BR>                                 <td styleCode="Rrule">67 (17%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Adjuvant only</td><BR>                                 <td styleCode="Rrule">104 (28%)</td><BR>                                 <td styleCode="Rrule">108 (27%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;No chemotherapy</td><BR>                                 <td styleCode="Rrule">203 (56%)</td><BR>                                 <td styleCode="Rrule">226 (56%)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>The efficacy results from the comparative study are shown in Table 10. The objective response rates observed in the two treatment arms showed that AROMASIN was not different from megestrol acetate. Response rates for AROMASIN from the two single-arm trials were 23.4% and 28.1%.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="90%"><BR>                           <caption>Table 10. Efficacy Results from the Comparative Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Tamoxifen Therapy</caption><BR>                           <col width="60%" align="left" valign="middle"/><BR>                           <col width="20%" align="center" valign="top"/><BR>                           <col width="20%" align="center" valign="top"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule">Response Characteristics</th><BR>                                 <th styleCode="Rrule" align="left">AROMASIN<br/>(N=366)</th><BR>                                 <th styleCode="Rrule" align="left">Megestrol Acetate<br/>(N=403)</th><BR>                              </tr><BR>                           </thead><BR>                           <tfoot><BR>                              <tr><BR>                                 <td colspan="3" align="left">Abbreviations:  CR = complete response, PR = partial response, SD = stable disease (no change), TTP = time to tumor progression, C.I. = confidence interval, MA = megestrol acetate, AR = AROMASIN</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Objective Response Rate = CR + PR (%)</td><BR>                                 <td styleCode="Rrule Botrule">15.0</td><BR>                                 <td styleCode="Rrule Botrule">12.4</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;Difference in Response Rate (AR-MA)<br/><BR>                                 </td><BR>                                 <td styleCode="Rrule" colspan="2">2.6<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;95% C.I.</td><BR>                                 <td styleCode="Rrule" colspan="2">7.5, -2.3</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">CR (%)</td><BR>                                 <td styleCode="Rrule">2.2</td><BR>                                 <td styleCode="Rrule">1.2</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">PR (%)</td><BR>                                 <td styleCode="Rrule">12.8</td><BR>                                 <td styleCode="Rrule">11.2</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;SD &#8805; 24 Weeks (%)</td><BR>                                 <td styleCode="Rrule">21.3</td><BR>                                 <td styleCode="Rrule">21.1</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Median Duration of Response (weeks)</td><BR>                                 <td styleCode="Rrule">76.1</td><BR>                                 <td styleCode="Rrule">71.0</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">Median TTP (weeks)</td><BR>                                 <td styleCode="Rrule">20.3</td><BR>                                 <td styleCode="Rrule">16.6</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;Hazard Ratio (AR-MA)</td><BR>                                 <td styleCode="Rrule Toprule" colspan="2">0.84</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>There were too few deaths occurring across treatment groups to draw conclusions on overall survival differences. The Kaplan-Meier curve for time to tumor progression in the comparative study is shown in Figure 2.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" styleCode="Noautorules"><BR>                           <caption>Figure 2. Time to Tumor Progression in the Comparative Study of Postmenopausal Women With Advanced Breast Cancer Whose Disease Had Progressed After Tamoxifen Therapy</caption><BR>                           <col width="100%" align="center" valign="top"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <renderMultiMedia referencedObject="MM3"/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                     <BR>                        <BR>                           Figure 2<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>